Altimmune Stock Analysis

Altimmune Stock Analysis Notes

About 40.0% of the company shares are held by institutions such as insurance companies. The book value of Altimmune was presently reported as 1.94. The company recorded a loss per share of 1.07. Altimmune last dividend was issued on the 20th of January 2017. The entity had 1:30 split on the 14th of September 2018. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. For more info on Altimmune please contact Vipin Garg at 240 654 1450 or go to https://altimmune.com.

Altimmune Investment Alerts

Altimmune Largest EPS Surprises

View All Earnings Estimates

Altimmune Environmental, Social, and Governance (ESG) Scores

Altimmune Stock Institutional Investors

Note, although Altimmune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Altimmune Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 609.88 M.

Altimmune Profitablity

Management Efficiency

Altimmune has Return on Asset of (0.3087) % which means that on every $100 spent on assets, it lost $0.3087. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.5262) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.82 in 2026. Return On Capital Employed is likely to drop to -0.76 in 2026. At this time, Altimmune's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 4.7 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 101.6 M in 2026.

Technical Drivers

As of the 8th of February, Altimmune shows the Downside Deviation of 5.73, risk adjusted performance of 0.0751, and Mean Deviation of 4.08. Altimmune technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Altimmune Price Movement Analysis

Altimmune Insider Trading Activities

Altimmune Outstanding Bonds

Altimmune Predictive Daily Indicators

Altimmune Forecast Models

Altimmune's time-series forecasting models are one of many Altimmune's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Altimmune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Altimmune Bond Ratings

Altimmune financial ratings play a critical role in determining how much Altimmune have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Altimmune's borrowing costs.

Altimmune Debt to Cash Allocation

Altimmune has 1.68 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. Altimmune has a current ratio of 13.84, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Nevertheless, prudent borrowing could serve as an effective mechanism for Altimmune to finance growth opportunities yielding strong returns.

Altimmune Total Assets Over Time

Altimmune Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Altimmune uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Altimmune Debt Ratio

1.32

It appears most of the Altimmune's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Altimmune's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Altimmune, which in turn will lower the firm's financial flexibility.

Altimmune Corporate Bonds Issued

Altimmune Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Altimmune prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Altimmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Altimmune. By using and applying Altimmune Stock analysis, traders can create a robust methodology for identifying Altimmune entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Altimmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Altimmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Altimmune stock analysis indicators help investors evaluate how Altimmune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Altimmune shares will generate the highest return on investment. By understating and applying Altimmune stock analysis, traders can identify Altimmune position entry and exit signals to maximize returns.

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.